About
Ncardia provides human iPSC-based products, assays, and custom services for drug discovery, disease modeling, toxicology, safety pharmacology, and regenerative medicine. It serves biopharmaceutical and research customers working on small molecules, RNA therapies, gene therapies, and biologics from sites in Europe and North America.
Services
iPSC products
Provides ready-to-use human iPSC-derived cell models manufactured to scale and available for cardiovascular, neural, vascular, and smooth muscle applications.
Custom iPSC reprogramming
Reprograms selected starting material into iPSCs for customer-specific research needs.
Custom iPSC differentiation
Differentiates iPSCs into functional cell types at the scale needed for screening, preclinical cell therapy, and tissue or organ engineering.
iPSC gene editing
Performs knock-out and knock-in editing using STAR-CRISPR technology.
iPSC-based assays
Develops iPSC-based assays for pilot studies, validation studies, and full screening campaigns.
Ready-to-use assays
Offers standardized iPSC-based screening assays for efficacy and safety studies.
Custom screening services
Develops disease-relevant screening assays and custom screening workflows tailored to specific research questions.
Drug discovery services
Supports target identification, hit finding, lead optimization, and preclinical candidate selection using iPSC-based models.
Disease modeling
Creates patient-derived, genome-edited, and environmentally induced disease models for research and screening.
Toxicology and safety pharmacology
Provides iPSC-based cardiotoxicity and neurotoxicity assessments for preclinical safety studies.
IO Safety Panel
Screens immuno-oncology programs across seven human iPSC-derived tissues in a single workflow to assess functional toxicity risks.
Small molecule screening platform
Uses iPSC-based human models and clinically relevant readouts to support small-molecule discovery.
RNA therapeutics screening platform
Supports screening and development of RNA therapeutics including siRNA, mRNA, ASOs, and miRNA using iPSC-based models.
Gene therapy screening platform
Supports gene therapy development with iPSC-derived models and screening assays.
Biologics discovery platform
Supports discovery of biologic drugs with assays for mechanism of action, efficacy, and potency.
iPSC Reprogramming
Select starting material and have it reprogrammed into iPSCs for downstream research use.
iPSC Differentiation
Differentiate iPSCs into functional cells at scale for screening, preclinical cell therapy, and tissue or organ engineering.
Custom Screening Applications
Build custom disease-relevant screening assays tailored to specific research questions.
Custom iPSC Cell Services
Coordinate sourcing, reprogramming, differentiation, and gene editing for patient- or disease-specific cellular models.
- Turnaround
- Quick turnaround
- What to send
- Preferred starting material for reprogramming · Tissue or cell samples for patient- or disease-specific model creation · Customer's own iPSC lines · Starting material for iPSC reprogramming · Your own iPSC lines · Tissue or cell samples for custom models
Capabilities
- Assays and studies
- Toxicology · Non-human primate · Small molecules · HTS · Cell therapy · CRISPR · High-content imaging · Flow cytometry · qPCR · Patch clamp · Efficacy screening · Safety screening
18 more
Cardiotoxicity · Neurotoxicity · Cardiac hypertrophy · Gene modulation · Endothelial barrier function · 3D cardiac microtissues · Cell viability · Cell morphology · Gene expression · Protein expression · Biomarker detection · Electrophysiological activity · Organelle characterization · Monoculture · Co-culture · Triculture · 2D formats · 3D formats - Scale and capacity
- Manufactured to scale · High-throughput screening campaigns · High-throughput production of genetically defined iPSC lines · Large-scale batches
- Therapeutic areas
- Drug discovery · Disease modeling · Regenerative medicine · Toxicology · Safety pharmacology · Neuroscience · Cardiac · Immune-oncology · Renal · Liver · Fibrosis · Cardiovascular
7 more
Neurological disorders · Parkinson's disease · Alzheimer's disease · ALS / FTD · Neuroinflammation · Cardiac hypertrophy · Endothelial barrier function
Instruments and platforms
- High Content Imaging
- Incucyte
- ImageXpress Confocal
- xCELLigence RTCA Cardio
- CardioExcyte 96
- Cytation
- BioRad Opus 384 qPCR
- RNAseq
- Whole genome sequencing
- Spark Multimode Microplate Reader
- NovoCyte Flow Cytometer
- Maestro MEA
- LUMO
- Automation for HTS
- Multi-Electrode Array (MEA)
- FDSS - Calcium Imaging
- Mesoscale Discovery Platform (MSD)
- FACS
- Plate Readers
- qPCR
Modalities and species
- Modalities
- Small molecule · Antibody · Oligonucleotide · mRNA · Cell therapy · Gene editing · Recombinant protein
- Species and models
- Human iPSC-derived cells · Ncyte® vCardiomyocytes · Ncyte® aCardiomyocytes · Ncyte® Endothelial Cells · Ncyte® Astrocytes · Ncyte® Microglia · Ncyte® GABAergic Neurons · Ncyte® Excitatory Neurons · Ncyte® Cholinergic Neurons · Ncyte® Motor Neurons · Ncyte® Dopaminergic Neurons · Ncyte® Sensory Neurons
8 more
Ncyte® Smooth Muscle Cells · NHP C vCardiomyocytes · Patient-derived iPSC lines · hiPSC-microglia · hiPSC-derived motor neurons · hiPSC-derived neurons · hiPSC-derived cardiomyocytes · hiPSC-derived astrocytes
Company
- Type
- CRO
- Quality
- Rigorous quality control (cell models and assays) · robust QA assays (identity, activity, and phenotypic relevance) · controlled conditions (iPSC-derived tissues in IO Safety Panel) · STAR-CRISPR (proprietary gene editing technology)
Locations
- Address
- Oortweg 21 2333 CH Leiden 2333 BD Leiden The Netherlands item.aria_lab
- Sites
- Leiden, The Netherlands
- Serves
- Europe, North America, worldwide
Public records
- Parent company
- Ncardia AG · DE GLEIF
Similar labs
Work here? Claim this listing